Lost in DCTH ......did a mistake of not taking profit on ups. Changed my game plan based of 6 year of biotech investing exp . Based on my exp Gale is going back 3.5 rage ......
Mark this post.
It is written on the walls. Wednesday open at $2.9
MGMT status has not shown any survival benefit.
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. The identification of novel molecular prognostic markers of GBM has recently been an area of great interest in neuro-oncology. The methylation status of the MGMT gene promoter is currently a promising molecular prognostic marker, but some controversial data have precluded its clinical use. We analyzed MGMT methylation by methylation-specific PCR in 90 GBM patients from four Portuguese hospitals, uniformly treated with radiotherapy combined with concomitant and adjuvant temozolomide (Stupp protocol). The Kaplan-Meier method was used to construct survival curves, and the log-rank test and a Cox-regression model were used to analyze patient survival. The methylation status of MGMT was successfully determined in 89% (80/90) of the tumors. The frequency of tumoral MGMT promoter methylation was 47.5%. The median overall survivals (OSs) were 16 months (95% CI 12.2-19.8) and 13 months (95% CI 13.3-18.7) for patients whose tumors had a methylated or unmethylated MGMT, respectively. Univariate and multivariate analyses did not show any statistically significant association between MGMT methylation status and patient OS (P=0.583 by the log-rank test; P=0.617 by the Cox-regression test) or progression-free survival (P=0.775 by the log-rank test; P=0.691 by the Cox-regression test). None of the patient clinical features were significantly correlated with survival. This is the first study to report the frequency of MGMT methylation among Portuguese GBM patients. Our data did not show statistically significant associations between MGMT promoter methylation and the outcome of GBM patients treated with temozolomide. Additional robust prospective studies are warranted to clarify whether the MGMT status should be used in clinical decisions.
A 600 patient Avastin Vs TMZ trial didi not show any relevance of extended survival with methylation patients. There is no randomize trial to prove this fact.
Such single center trial are as good as drinking lemon water to cure cancer as per old granny advice.
It seems , there is BIG news tomorrow .......As per IHUB post PPHM website is down.
Quite unusual .........Ready for partnership news tomorrow.
See u at $3.5
As per latest SNO abstract in P1 trial 50% patients were alive after 5 year (60 month) but Median overall survival is still 38 month ........Shouldn't it be 60 Month.
Got some new information from the presentation.
One of the slide shows that there was almost 10 week delay from GBM diagnosis to enrollment in trial.
This mean ICT-107 can still show 9 month survival advantage even if 64 th event occurs in Q4.
Any model Guru (phises3 or disco) ......what is your thought.
I think stock is on verge of breakout in next few weeks.
As per my model 2 week trial extension equal to 1 month extra survival advantage.